CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Two steps are better than one: improving gene editing to treat cancer.
Two steps are better than one: improving gene editing to treat cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
基因编辑使科学家能够利用细胞自身修复受损 DNA 的能力,并使用所提供的 DNA 模板,对生物体基因组进行精确改变。近年来,基因编辑已在癌症等疾病的治疗中应用于临床。基因编辑已被用于一种称为嵌合抗原受体表达 T 细胞(CAR-T)疗法的免疫治疗中,以恢复机体发现并杀死特定癌细胞的能力。对于这种疗法,病毒常被用来向细胞提供用于在目标 DNA 中创建编辑的 DNA 模板。然而,在这种情况下使用病毒既费力又昂贵。开发用于递送基因编辑 DNA 模板的非病毒方法将规避这些问题,但当前的方法可能对细胞产生毒性作用,并导致较低的编辑效率。在本期发表的一篇新文章中,Yang 等人描述了一种不依赖病毒递送裸 DNA 并将其整合到基因组中以工程化用于 CAR-T 疗法的细胞的新方法。
Gene editing enables scientists to make precise changes to the genome of an organism using the cell's own ability to repair damaged DNA using a supplied DNA template. In recent years, gene editing has been applied clinically in the treatment of diseases such as cancer.
Gene editing has been used in a type of immunotherapy, known as chimeric antigen receptor-expressing T cell (CAR-T) therapy, to restore the body's ability to find and kill specific cancer cells. For this therapy, viruses are often used to supply the cell with the DNA template used for creating the edit in the target DNA.
However, the use of viruses in this context is laborious and costly. Developing non-viral methods for delivery of DNA templates for gene editing would circumvent these problems, but current methods can have toxic effects on cells and result in low editing efficiency. In a new article published in this issue, Yang et al. describe a novel method for viral-independent delivery of naked DNA and its incorporation into the genome for engineering cells for CAR-T therapy.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。